TTF-1 in extra-pulmonary adenocarcinoma (excluding thyroid neoplasms)

Note that the data listed in this table is, where stated, for clone 8G7G3/1 or for polyclonal antibody.  For the lower specificity of clone SPT24, see TTF-1 monoclonal comparison.

Breast

4/551 (0/965, 0/1815, 0/519, 0/723, 0/534, 0/106, 0/137, 0/89, 0/511, 0/28, 0/2535, 0/1139, 0/643, 0/644, 0/610, 0/1245, 0/446, 0/2447, 0/1248, 0/1149, 0/1249, 0/3550, 0/552, 0/3053, 4/556, 0/1757, 0/11558)

Salivary gland

0/323

Gastrointestinal tract

0/1245, 0/1647, 0/1448, 0/649

Oesophagus

0/315, 0/2150

Stomach

3/188 (1/661, 0/315, 0/519, 0/2431, 0/2, 0/9, 1/2339, 0/1149, 1/3450, 0/1152)

Colon

4/476 ( 0/181, 0/212, 0/304 , 0/206, 0/26, 0/3, 0/8, 0/6, 0/5, 0/26, 0/519, 0/123, 0/3531, 0/1634, 0/10, 0/2539, 0/5040, 0/144, 0/249, 0/4750, 0/252, 0/557 , 4/1459, 0/10059)

Liver

0/226, 0/2, 0/46, 0/149, 0/650, 0/152

Gallbladder

 0/115, 0/1039, 0/1, 0/1050

Ampulla of Vater

0/650

Pancreas

0/108 (0/215, 0/731, 0/1539, 1/5350, 0/3157)

Genitourinary tract

0/3447

Kidney

0/86 (0/185, 0/1423, 0/934, 0/77, 0/81, 0/28, 0/1035, 0/144, 0/2, 0/1550, 0/11857)

Bladder

0/3

Ovary

29/556 (0/305, 1/1615, 0/1531, 15/5333, 0/234, 0/15, 0/4, 0/30, 2/16636, 9/3442, 2/13842, 0/1245, 0/146, 0/49, 0/2850, 0/652) 1/155

Endometrium

7/97 (1/81, 0/415, 0/2531, 0/334, 0/16, 0/6, 6/3237, 3/1337, 0/1, 0/1050), 154

Cervix uteri

1/2837

Peritoneal serous carcinoma

1/1338

Prostate

0/56 (0/195, 0/215, 0/9, 0/1, 0/10, 0/1539, 2/2941, 0/44, 0/146, 2/1850, 151)

paranasal sinus

0/44

Total

18/534 (2/2865, 1/4915, 0/1519, 0/2523, 0/10631, 15/5333)

15†using cell blocks from FNAs

I have seen one focally positive colorectal metastasis to lung (unpublished case).

References

1 Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996; 9:445-52

2Holzinger A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 1996; 15:49-53

3 Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000; 24:1217-23

4 Kaufmann O,Dietel M Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000; 36:8-16

5 Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Advances in Anatomic Pathology 2000; 7(2): 123-127.

6 Chang YL, Lee YC, Liao WY, et al. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004; 44:149-57

7 Moldvay J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004; 10:85-8

8 Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? Pathol Res Pract 2000; 196:835-40

9 Jang KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001; 23:400-4

10 Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001; 93:330-6 FULL TEXT

11 Ng WK, Chow JC,Ng PK Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 2002; 96:43-8

12 Wieczorek TJ, Pinkus JL, Glickman JN, et al. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol 2002; 118:911-21

15 Hecht, J. L., Pinkus, J. L., Weinstein, L. J., Pinkus, G. S. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin Am J Clin Pathol 2001;116:483-488.

19 Merchant, S.H., Amin, M.B., Tamboli, P., Ro, J., Ordonez, N.G., Ayala, A.G., Czerniak, B.A. and Ro, J.Y. Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas. Am J Surg Pathol 2001;25:1515-9.

23 Srodon, M. and Westra, W.H. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol 2002;33:642-5.

31 Stenhouse, G., N. Fyfe, et al. (2004). "Thyroid transcription factor 1 in pulmonary adenocarcinoma." J Clin Pathol 57(4): 383-7.

33 Quddus MR et al. Expression of TTF-1 in primary ovarian surface epithelial carcinomas: a study of 53 cases. Modern Pathology 2004 17(1):211A.

34 Jerome Marson, V., J. Mazieres, et al. (2004). "Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade." Histopathology 45(2): 125-34.

35 Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24:598-606.

36 Graham AD, Williams AR,Salter DM TTF-1 expression in primary ovarian epithelial neoplasia. Histopathology 2006; 48:764-5

37 Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2007; 31:1759-63 (published data suplemented with information kindly provided by Dr Deavers)

38 Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006; 125:67-76 CHECK

39 Nakamura N, Miyagi E, Murata S, et al. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol 2002; 15:1058-67

40 Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131:1561-7 FULL TEXT

41 Leite KR, Mitteldorf CA, Srougi M, et al. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer. Ann Diagn Pathol 2008; 12:260-6

42 Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol 2008; 21:485-90

43 Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998; 42:1382-8

44 Bohinski RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1. J Neurooncol 1998; 40:227-31

45Afify AM,al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 2002; 46:675-8

46 Roh MS,Hong SH. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. J Korean Med Sci 2002; 17:512-7 FULL TEXT

47 Gomez-Fernandez C, Jorda M, Delgado PI, et al. Thyroid transcription factor 1: a marker for lung adenoarinoma in body cavity fluids. Cancer 2002; 96:289-93

48 Su YC, Hsu YC,Chai CY. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci 2006; 22:14-9 FULL TEXT

49 Strickland-Marmol LB, Khoor A, Livingston SK, et al. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med 2007; 131:1686-90 FULL TEXT

50 Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11:3766-72 FULL TEXT

51 Lim TK, Teo C, Giron DM, et al. Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate:a potential pitfall. J Clin Pathol 2007; 60:941-3

52 Jan IS, Chung PF, Weng MH, et al. Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique. J Formos Med Assoc 2006; 105:695-700

53 Bisceglia M, Ragazzi M, Galliani CA, et al. TTF-1 expression in nephroblastoma. Am J Surg Pathol 2009; 33:454-61

54 Deavers MT Immunohistochemistry in gynecologic pathology. Arch Pathol Lab Med 2008; 132:175-80 FULL TEXT

55 Agaimy A,Wunsch PH. Unexpected and potentially misleading TTF-1 expression: a word of caution. Virchows Arch 2006; 449:603-5

56 Yamamoto J, Ohshima K, Nabeshima K, et al. Comparative study of primary mammary small cell carcinoma, carcinoma with endocrine features and invasive ductal carcinoma. Oncol Rep 2004; 11:825-31

57 Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010 Jan;41(1):20-5. (TTF-1 clone 8G7G3/1 used, confirmed by author)

58 Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010 May;23(5):654-61. (with corrections to the paper provided by author)

59 Xu B, Thong N, Tan D, Khoury T. Expression of thyroid transcription factor-1 in colorectal carcinoma. Appl Immunohistochem Mol Morphol. 2010 May;18(3):244-9.

This page last revised 16.5.2010.

 

©SMUHT/PW Bishop